TCPG
AZN icon

Trivant Custom Portfolio Group’s AstraZeneca AZN Stock Holding History

Trivant Custom Portfolio Group’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,489
Closed -$1.15M – 186
2024
Q1 		$1.15M Buy
8,489
+458
+6% +$60.6K 0.73% 41
2023
Q4 		$1.08M Sell
8,031
-1,670
-17% -$217K 0.72% 40
2023
Q3 		$1.31M Buy
9,701
+241
+3% +$32.9K 0.97% 39
2023
Q2 		$1.35M Buy
+9,460
New +$1.39M 0.96% 39

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Trivant Custom Portfolio Group's AZN Position: Q2 2024 in Review

Trivant Custom Portfolio Group sold out of AstraZeneca (AZN) in Q2 2024, closing a stake of 8,489 shares — an estimated $1.15M sold.

Trivant Custom Portfolio Group first reported a position in AZN in Q2 2023 and held it in 4 quarters. The position peaked at $1.35M in Q2 2023. 1,211 funds tracked by Wall St. Rank hold AZN as of Q2 2024.

  • Trivant Custom Portfolio Group reported no remaining AstraZeneca position as of Q2 2024 after selling out during the quarter.
  • Trivant Custom Portfolio Group sold 8,489 AstraZeneca shares in Q2 2024, an estimated $1.15M.
  • Trivant Custom Portfolio Group first reported a position in AstraZeneca in Q2 2023 and held it in 4 quarters.
  • Trivant Custom Portfolio Group's AstraZeneca position peaked at $1.35M in Q2 2023.
  • 1,211 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2024.

Based on Trivant Custom Portfolio Group's 13F filing for Q2 2024, filed 17 Jul 2024.